Sandoz has recruited Teva’s Karan Ambwani to head up the Novartis unit’s strategy, business development and portfolio in Europe. Meanwhile, Diane DiGangi Trench is moving from Sandoz US to head up the company’s operations in the UK.

India and China have once again come under fire from the US over intellectual property protections, in the US Trade Representative’s latest “Special 301” report.

Hikma has added to its injectables portfolio in the US with the launches of dexmedetomidine and docetaxel.

Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.

Despite turnover dropping by over a fifth in its financial third quarter, Lannett says it is optimistic that respiratory generics and insulins will offer the firm “durable” opportunities in future. The company has also just reorganized its finances to extend its debt maturity by four years, pushing it back past some of its key launches.